ONCAlert | 2018 ASCO Annual Meeting

Acute Myeloid Leukemia MORE >>

Ivosidenib (Tibsovo) has been granted approval by the FDA for the treatment of adult patients with relapsed/refractory IDH1-mutant acute myeloid leukemia.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.